Towards rapid measurement of antibiotics in critical care setting
在重症监护环境中快速测量抗生素
基本信息
- 批准号:10693403
- 负责人:
- 金额:$ 67.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffinityAminoglycosidesAntibiotic ResistanceAntibioticsBinding ProteinsBiologicalBiological AssayBiosensorBuffersCalibrationChemicalsChromatographyClinicalClinical ChemistryComplexConsensusCoupledCritical CareCritical IllnessDaptomycinDecision MakingDevicesDialysis procedureDoseDrug KineticsDrug MonitoringFailureFamilyFluoroquinolonesFoundationsFrequenciesFundingGlycopeptidesGoalsHospitalizationHospitalsImmunoassayIndividualLaboratoriesLinezolidLiquid substanceMeasurementMeasuresMethodsMonitorNatureOligonucleotidesOrganPatientsPharmaceutical PreparationsPhysiciansPhysiologicalPlasmaPolymyxinsPreparationProcessPropertyProtocols documentationReagentRegimenRenal Replacement TherapyReportingSamplingSerumStandardizationSurfaceTechnologyTestingTherapeuticTimeUltrafiltrationVancomycinVariantWhole BloodWorkanalytical methodaptamerbacterial resistancebeta-Lactamscandidate validationclinical decision-makingclinical practicecompare effectivenesscostcost effectivecross reactivitydesigngraphenenanomaterialsneglectnew chemical entityreceptorresponsesensorsmall moleculestandard of caretheories
项目摘要
Summary:
Delivering antibiotics (or other drugs) at effective and safe concentrations to unstable, critically ill hospitalized
patients is a daunting problem – for example, for all six antibiotics that are the focus of this work, pharmacokinetic
studies reveal truly wide discrepancies between predicted and actual active concentrations. While important
strides have been made to help physicians make decisions that are most likely to help, and least likely to harm,
an important cornerstone for such approaches is still missing: There are no clinically validated devices that can
rapidly, accurately and precisely measure concentrations of drugs in a manner that would address the long turn-
around-times and prohibitive cost of the central-laboratory-based approach to high-frequency therapeutic drug
monitoring. We approach the problem systematically from the bottom up by building and validating at each step
each of the components needed to overcome such barriers.
As our first challenge (and our first Aim), we focus on high-quality receptors – well characterized and validated
on their own – which could then be widely used and implemented by other groups in different formats, by simply
being ordered “off the shelf”. We identified oligonucleotide-based receptors (aptamers) as such reagents.
Building on our vast preliminary results, we delineate a process that will lead to isolation of sets of receptors,
with each candidate validated on its own in a fluorescent format against gold-standard analytical methods in
patient-derived fluids, under conditions that allow these simple sensors to be applied directly in mix-and-measure
formats (e.g., dialysis effluents, ultrafiltered sera, and extracts from standard SPE columns).
Our second challenge, exacerbated by the highly variable nature of samples collected from critically ill patients,
is cross-reactivity and deviations from standardized conditions. We address these by identifying pairs of
aptamers with orthogonal properties for each antibiotic: One of the aptamers will be used in biosensor modules
(Aim 2) under strictly controlled conditions in conjunction with a commonly used nanomaterial (graphene) and
validated on dialysis effluents and extracts from SPE columns (here, biosensors can be used without pre-
purification) against gold-standard chromatographic methods. The other aptamer from the pair, from an unrelated
family, will be comprehensively validated as the affinity component of extraction modules (Aim 3) on spiked
commercial samples of sera and actual samples from critically ill patients.
Through this approach, we will provide rigorously characterized, standardized components for analysis of
polymyxins, fluoroquinolones, daptomycin, linezolid, and beta lactams, which will enable us (and others) to
combine components into devices, either to be used at the bedside, or as cartridges in automatized analyzers.
In either case, these will facilitate routine high-frequency drug monitoring outside of large, academic hospital
settings. We expect to demonstrate one design of multi-modular devices by the end of this funding period.
简介:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Serge Cremers其他文献
Serge Cremers的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Serge Cremers', 18)}}的其他基金
Towards rapid measurement of antibiotics in critical care setting
在重症监护环境中快速测量抗生素
- 批准号:
10522146 - 财政年份:2022
- 资助金额:
$ 67.62万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 67.62万 - 项目类别:
Continuing Grant